FDA Approves New Bleeding Antidote Andexxa

There is promising news for the more than 4 million patients who take Xarelto® (Riviaroxaban) or Eliquis® (Aixaban) on a daily basis. These blood thinners, while effective, have been shown to cause uncontrolled and sometimes life-threatening bleeding events.  The FDA has finally approved a reversal agent that can stop the anticoagulant effects of Xa inhibitors, in the form…

Details